Exclusive licensing agreement combines Lonza’s dual-payload ADC technology with Antharis’ antibody engineering expertise
Cervical cancer remains one of the leading causes of cancer deaths among women in India
The approval clears the company to market a generic version that is therapeutically equivalent to Retin-A Cream
The decision was driven by results from the Phase III CAPItello-281 trial,
Despite the disruption, the company stressed that “our core business operations are not impacted and remain up and running.
Dr. Quirk said the program’s mechanism offers a targeted approach to disrupted brain signaling in compulsivity-related disorders
Health Ministry reviews progress, highlights targeted interventions in high-burden states, and calls for stronger surveillance and stigma reduction to achieve a leprosy-free India
Molbio Diagnostics' Truenat HPV-HR Plus becomes the world's first formally validated reduced-valency HPV test, meeting WHO-IARC standards
The regulatory decision follows promising results from RIVER-81
Approval is based on results from the phase 3 OASIS 4 clinical trial
Subscribe To Our Newsletter & Stay Updated
